Matica Biotechnology, Inc., which happens to be a leading contract development and manufacturing organization (CDMO) that specializes in viral vector manufacturing in terms of cell and gene therapies, announced on September 15, a strategic commercial manufacturing deal along with a clinical-stage biotech company that’s based in the US.
This partnership is going to mark a prominent landmark as Matica Bio initiates GMP production of viral vectors so as to support the development of a novel advanced therapy that targets a serious and underserved disease area.
As per the agreement, Matica Bio is going to offer technology transfer, analytical testing, process scale-up, and commercial-scale GMP manufacturing services. All these activities are going to support the Biologics License Application (BLA) submission and also certain future commercial supplies when it comes to the medicine.
According to the CEO of Matica Bio, Paul Kim, this collaboration happens to reflect the ability of Matica Bio to support advanced therapeutic development right from the early development stage to all through the details mentioned in the commercial manufacturing deal, under strict regulatory compliance. He added that they are indeed proud to go ahead and contribute their capabilities to one of the pioneering novel programs, which happens to have the potential to transform treatment choices for patients who are in need. Due to the advanced technology of Matica Bio, such as the manufacturing platform, which is built on the proprietary MatiMax™ cell line, along with advanced analytical capabilities that include the likes of outstanding empty or full capsid ratio analysis, they go on to demonstrate true expertise when it comes to delivering successful products for certain intricate CGT programs in a market that’s continuously evolving and also governed by stringent regulatory needs.
